Response definition criteria for ELISPOT assays revisited
Top Cited Papers
Open Access
- 15 June 2010
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 59 (10) , 1489-1501
- https://doi.org/10.1007/s00262-010-0875-4
Abstract
No consensus has been reached on how to determine if an immune response has been detected based on raw data from an ELISPOT assay. The goal of this paper is to enable investigators to understand and readily implement currently available methods for response determination. We describe empirical and statistical approaches, identifying the strengths and limitations of each approach to allow readers to rationally select and apply a scientifically sound method appropriate to their specific laboratory setting. Five representative approaches were applied to data sets from the CIMT Immunoguiding Program and the response detection and false positive rates were compared. Simulation studies were also performed to compare empirical and statistical approaches. Based on these, we recommend the use of a non-parametric statistical test. Further, we recommend that six medium control wells or four wells each for both medium control and experimental conditions be performed to increase the sensitivity in detecting a response, that replicates with large variation in spot counts be filtered out, and that positive responses arising from experimental spot counts below the estimated limit of detection be interpreted with caution. Moreover, a web-based user interface was developed to allow easy access to the recommended statistical methods. This interface allows the user to upload data from an ELISPOT assay and obtain an output file of the binary responses.Keywords
This publication has 23 references indexed in Scilit:
- Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding ProgramCancer Immunology, Immunotherapy, 2010
- Identification of Major Factors Influencing ELISpot-Based Monitoring of Cellular Responses to Antigens from Mycobacterium tuberculosisPLOS ONE, 2009
- “MIATA”—Minimal Information about T Cell AssaysImmunity, 2009
- A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"Journal of Translational Medicine, 2008
- Immunological Outcomes of New Tuberculosis Vaccine Trials: WHO Panel RecommendationsPLoS Medicine, 2008
- HLA class I supertypes: a revised and updated classificationBMC Immunology, 2008
- Precision and linearity targets for validation of an IFNγ ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptidesBMC Immunology, 2008
- Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Cancer Immunology, Immunotherapy, 2007
- Toward the harmonization of immune monitoring in clinical trials: Quo vadis?Cancer Immunology, Immunotherapy, 2007
- The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assaysCancer Immunology, Immunotherapy, 2007